Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available
Crossref DOI link: https://doi.org/10.1007/s40273-016-0401-4
Published Online: 2016-03-22
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Beauchemin, Catherine
Lapierre, Marie-Ève
Letarte, Nathalie
Yelle, Louise
Lachaine, Jean
Funding for this research was provided by:
Canadian Institute for Health Research (Doctoral Research Award)
Text and Data Mining valid from 2016-03-22